- Home
- TKLF vs CMMB Comparison
TKLF vs CMMB Comparison
Compare TKLF & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- CMMB
- Stock Information
- Founded
- TKLF 2006
- CMMB 2004
- Country
- TKLF Japan
- CMMB Israel
- Employees
- TKLF N/A
- CMMB N/A
- Industry
- TKLF Other Specialty Stores
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- CMMB Health Care
- Exchange
- TKLF Nasdaq
- CMMB Nasdaq
- Market Cap
- TKLF 15.6M
- CMMB 13.7M
- IPO Year
- TKLF 2022
- CMMB N/A
- Fundamental
- Price
- TKLF N/A
- CMMB $3.50
- Analyst Decision
- TKLF
- CMMB Strong Buy
- Analyst Count
- TKLF 0
- CMMB 2
- Target Price
- TKLF N/A
- CMMB $26.50
- AVG Volume (30 Days)
- TKLF 20.7K
- CMMB 214.4K
- Earning Date
- TKLF 07-10-2025
- CMMB 11-13-2025
- Dividend Yield
- TKLF N/A
- CMMB N/A
- EPS Growth
- TKLF N/A
- CMMB N/A
- EPS
- TKLF 1.57
- CMMB N/A
- Revenue
- TKLF $210,119,238.00
- CMMB N/A
- Revenue This Year
- TKLF N/A
- CMMB N/A
- Revenue Next Year
- TKLF N/A
- CMMB N/A
- P/E Ratio
- TKLF $2.34
- CMMB N/A
- Revenue Growth
- TKLF 7.38
- CMMB N/A
- 52 Week Low
- TKLF $2.20
- CMMB $2.39
- 52 Week High
- TKLF $5.80
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- TKLF 47.73
- CMMB 76.10
- Support Level
- TKLF $3.56
- CMMB $2.60
- Resistance Level
- TKLF $3.74
- CMMB $2.79
- Average True Range (ATR)
- TKLF 0.20
- CMMB 0.16
- MACD
- TKLF -0.01
- CMMB 0.02
- Stochastic Oscillator
- TKLF 32.87
- CMMB 90.50
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.